RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Crohn’s disease (CD) and ulcerative colitis (UC) have features that suggest bacterial involvement, and all genetic models of inflammatory bowel disease (IBD)require the presence of commensal bacteria. CD is associated with innate immune response genes such as NOD2/CARD15 and the autophagy genes ATG16L1 and IRGM. However, IBD responds to immunosuppression,suggesting that any bacteria involved are not acting as conventional pathogens.
Molecular techniques are rapidly advancing our knowledge of the gut microbiota. In CD there is reduced diversity,and notably a reduction in the probiotic Faecalibacterium prausnitzii, the presence of which in the terminal ileum is associated with a reduced risk of recurrence following surgery. There is also a consistent increase in mucosa-associated Escherichia coli with an “adherent and invasive” phenotype, which allows them to replicate inside macrophages and induce granulomas. Speculation that CD could be caused by the Mycobacterium avium subspecies paratuberculosis (MAP) continues. The response to antitumor necrosis factor treatments suggests that, if relevant at all, MAP is not acting as a conventional pathogen. However,there is increased colonization by MAP in CD, and there is evidence that it could have an indirect effect mediated by the suppression of macrophage function.
UC relapse is frequently associated with infection by pathogens, but there is less evidence for involvement of a specific bacterial species. Poor barrier integrity followed by an inflammatory reaction to bacterial components,with chronicity maintained by an autoimmune process, seems a plausible pathogenic model.
Bacterial theories of pathogenesis are now becoming testable by targeted therapeutic interventions.

참고문헌 (Reference)

1 Hase K, "Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response" 462 : 226-230, 2009

2 Selby W, "Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease" 132 : 2313-2319, 2007

3 Willing B, "Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease" 15 : 653-660, 2009

4 Borody TJ, "Treatment of ulcerative colitis using fecal bacteriotherapy" 37 : 42-47, 2003

5 Mysore JV, "Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound" 117 : 1316-1325, 1999

6 Schulte R, "Translocation of Yersinia entrocolitica across reconstituted intestinal epithelial monolayers is triggered by Yersinia invasin binding to beta1 integrins apically expressed on M-like cells" 2 : 173-185, 2000

7 Clayton EM, "The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatientsetting among patients in remission" 104 : 1162-1169, 2009

8 Rhodes JM, "The role of Escherichia coli in inflammatory bowel disease" 56 : 610-612, 2007

9 Van Limbergen J, "The genetics of Crohn's disease" 10 : 89-116, 2009

10 Garside P, "The anatomy of mucosalimmune responses" 1029 : 9-15, 2004